ProCE Banner Activity

Phase III PETALs Interim Analysis: Nilotinib ± PegIFN alfa-2a in Patients With Newly Diagnosed Ph-Positive CP CML

Slideset Download
Conference Coverage
Combining peginterferon-alfa 2a with nilotinib in patients with chronic-phase CML showed significantly better rates of deep molecular response than nilotinib alone.

Released: December 19, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology